Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron
Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024
Combination dose escalation study starting with HR+/HER2- breast cancer to commence in late 2024/early 2025
Exscientia plc (NASDAQ:EXAI) today announced it has reached an agreement to acquire GT Apeiron's share of its oral CDK7 inhibitor programme, gaining full control of GTAEXS617 (‘617) and all related intellectual property.
The monotherapy dose escalation phase of ELUCIDATE is designed to assess the safety, pharmacokinetics and pharmacodynamics of '617 in advanced solid tumours. R
